Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer

The clinical utility of the percent of positive prostate biopsies in predic ting prostate-specific antigen (PSA) outcome following radical prostatectom y (RP), or external beam radiation therapy (RT), for men with PSA detected, or clinically palpable prostate cancer was investigated. After accounting for the established prognostic significance of the PSA lev el, biopsy Gleason score and the clinical T-stage, the percent of positive prostate biopsies added clinically significant information regarding time t o PSA failure following RP. These findings were validated in the intermedia te risk patients using an independent surgical and radiation data set.